IR-Med, Inc. (IRME) Stock Analysis
IR-Med, Inc. (IRME) Stock Analysis
Overall Grade: F (Concerning)
View interactive company profile →
IR-Med, Inc. faces challenges in financial performance that warrant careful analysis.
Key Metrics:
| Metric | Value | Context |
|---|---|---|
| ROIC | 308.9% | Above industry average |
| FCF Margin | 0.0% | Cash flow pressure |
| Debt/Equity | 0.0x | Conservative leverage |
Investment Thesis: Strong return on invested capital of 308.9% suggests durable competitive advantages and efficient capital allocation.
What is IR-Med, Inc.'s Profitability and ROIC?
IR-Med, Inc. generates strong returns on invested capital at 308.9%, indicating efficient capital allocation and competitive advantages.
Key Metrics
| Metric | Value | Rating | Interpretation |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 308.9% | Excellent | Strong capital efficiency |
| Return on Equity (ROE) | 1026.2% | Excellent | Efficient use of shareholder equity |
How Strong is IR-Med, Inc.'s Cash Flow Quality?
IR-Med, Inc. generated $-837000 in free cash flow over the trailing twelve months, representing a 0.0% margin. FCF was positive in N/A of the last 8 quarters, indicating variable cash generation.
Key Metrics
| Metric | Value | Rating | Interpretation |
|---|---|---|---|
| Free Cash Flow Margin | 0.0% | Red flag | Thin cash margins |
| Free Cash Flow (TTM) | $-837000 | Red flag | Cash burn |
| OCF/Net Income | 0.4x | Warning | Potential accrual concerns |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
What is IR-Med, Inc.'s Financial Health?
IR-Med, Inc.'s debt-to-equity ratio of 0.0x indicates conservative leverage.
Key Metrics
| Metric | Value | Rating | Interpretation |
|---|---|---|---|
| Debt to Equity | 0.0x | Excellent | Conservative capital structure |
Is IR-Med, Inc. Stock Overvalued or Undervalued?
Key Metrics
| Metric | Value | Rating | Interpretation |
|---|---|---|---|
| EV/Sales | 0.0x | Excellent | Attractive revenue multiple |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 308.9% | Top 5% | - |
| Free Cash Flow Margin | 0.0% | Bottom 10% | - |
| Return on Equity (ROE) | 1026.2% | Top 5% | - |
Rating Thresholds
Return on Invested Capital (ROIC)
Measures how efficiently a company uses its debt and equity capital to generate profits. ROIC above 15% typically indicates a competitive moat.
| Rating | Range | Interpretation |
|---|---|---|
| Excellent | > 20% | Exceptional capital efficiency, strong competitive moat |
| Good | 12% - 20% | Above-average returns, sustainable competitive position |
| Adequate | 8% - 12% | Around cost of capital, moderate competitive position |
| Warning | 4% - 8% | Below cost of capital, value may be eroding |
| Red flag | < 4% | Significant capital destruction, fundamental issues |
Current: 308.9% (Excellent - Top 5% of sector (median: 0.0%))
Free Cash Flow Margin
The percentage of revenue converted to free cash flow. Higher margins indicate stronger cash generation and business quality.
| Rating | Range | Interpretation |
|---|---|---|
| Excellent | > 20% | Strong cash generation, high-quality business |
| Good | 10% - 20% | Healthy cash conversion |
| Adequate | 5% - 10% | Moderate cash generation |
| Warning | 0% - 5% | Thin cash margins, capital intensive |
| Red flag | < 0% | Cash burn, potential liquidity concerns |
Current: 0.0% (Red flag)
Debt to Equity Ratio
Total debt divided by shareholders' equity. Lower ratios indicate more conservative financing and reduced financial risk.
| Rating | Range | Interpretation |
|---|---|---|
| Excellent | < 0.3x | Conservative leverage, strong balance sheet |
| Good | 0.3x - 0.7x | Moderate leverage, healthy financial position |
| Adequate | 0.7x - 1.5x | Elevated leverage, monitor closely |
| Warning | 1.5x - 3.0x | High leverage, increased financial risk |
| Red flag | > 3.0x | Excessive leverage, potential distress risk |
Current: 0.0% (Excellent)
Frequently Asked Questions
Q: What is IR-Med, Inc.'s Return on Invested Capital (ROIC)?
IR-Med, Inc. (IRME) has a trailing twelve-month Return on Invested Capital (ROIC) of 308.9%. This compares above the sector median of 0.0%. An ROIC above 20% indicates exceptional capital efficiency and strong competitive advantages.
Q: What is IR-Med, Inc.'s Free Cash Flow Margin?
IR-Med, Inc. (IRME) has a free cash flow margin of 0.0%, generating $-837000 in free cash flow over the trailing twelve months. Negative free cash flow means the company is consuming cash, which may require financing.
Q: Is IR-Med, Inc. stock overvalued or undervalued?
IR-Med, Inc. (IRME) The EV/Sales multiple is 0.0x.
Q: What is IR-Med, Inc.'s revenue and earnings growth?
IR-Med, Inc. (IRME) Earnings per share increased by 33.3% compared to the prior year.
Q: How does IR-Med, Inc. compare to competitors in Healthcare?
Compared to other companies in Healthcare, IR-Med, Inc. (IRME) shows: ROIC of 308.9% is above the sector median of 0.0% (Top 0%). FCF margin of 0.0% trails the sector median of 0.0%. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with IR-Med, Inc.?
Investors in IR-Med, Inc. (IRME) should monitor these potential warning signs: 1) FCF margin is thin at 0.0%, leaving limited buffer for economic downturns. Regular monitoring of SEC filings and quarterly trends is recommended.
Data Source: Data sourced from 10-Q filed 2025-08-14. TTM metrics as of Q2 2025.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
This analysis is for informational purposes only and does not constitute investment advice.